- Home
- RIGL vs OI Comparison
RIGL vs OI Comparison
Compare RIGL & OI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | OI |
|---|---|---|
| Founded | 1996 | 1903 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Containers/Packaging |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.8M | 932.7M |
| IPO Year | 2000 | 1994 |
Fundamental Metrics
Financial Performance| Metric | RIGL | OI |
|---|---|---|
| Price | $51.03 | $5.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $63.00 | $6.50 |
| AVG Volume (30 Days) | 187.5K | ★ 3.8M |
| Earning Date | 11-05-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | $294,282,000.00 | ★ $6,426,000,000.00 |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $21.95 | $0.68 |
| P/E Ratio | $38.83 | ★ N/A |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $5.21 |
| 52 Week High | $52.24 | $16.91 |
Technical Indicators
Market Signals| Indicator | RIGL | OI |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 30.02 |
| Support Level | $44.83 | N/A |
| Resistance Level | N/A | $9.63 |
| Average True Range (ATR) | 1.53 | 0.30 |
| MACD | 0.30 | -0.06 |
| Stochastic Oscillator | 75.79 | 4.57 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About OI O-I Glass Inc.
O-I Glass is the manufacturer of glass containers. The Company has two reportable segments and two operating segments based on its geographic locations: Americas and Europe. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food.